ProShare Advisors LLC Increases Holdings in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)


Share on StockTwits

ProShare Advisors LLC boosted its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 12.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 258,014 shares of the biopharmaceutical company’s stock after buying an additional 29,300 shares during the quarter. ProShare Advisors LLC owned 0.12% of Alexion Pharmaceuticals worth $40,312,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Profund Advisors LLC lifted its holdings in Alexion Pharmaceuticals by 8.1% in the 4th quarter. Profund Advisors LLC now owns 59,900 shares of the biopharmaceutical company’s stock worth $9,359,000 after buying an additional 4,503 shares in the last quarter. Thompson Siegel & Walmsley LLC lifted its holdings in Alexion Pharmaceuticals by 3.3% in the 4th quarter. Thompson Siegel & Walmsley LLC now owns 659,432 shares of the biopharmaceutical company’s stock worth $103,030,000 after buying an additional 20,947 shares in the last quarter. Philadelphia Trust Co. lifted its holdings in Alexion Pharmaceuticals by 8.6% in the 4th quarter. Philadelphia Trust Co. now owns 3,800 shares of the biopharmaceutical company’s stock worth $594,000 after buying an additional 300 shares in the last quarter. FDx Advisors Inc. acquired a new position in Alexion Pharmaceuticals in the 4th quarter worth $254,000. Finally, Lido Advisors LLC acquired a new position in Alexion Pharmaceuticals in the 4th quarter worth $256,000. Hedge funds and other institutional investors own 87.27% of the company’s stock.

In related news, CAO Tanisha Carino sold 1,530 shares of the stock in a transaction that occurred on Thursday, December 3rd. The shares were sold at an average price of $122.26, for a total transaction of $187,057.80. Following the completion of the sale, the chief accounting officer now directly owns 17,632 shares of the company’s stock, valued at $2,155,688.32. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Daniel Bazarko sold 24,066 shares of the stock in a transaction that occurred on Thursday, December 17th. The shares were sold at an average price of $157.70, for a total transaction of $3,795,208.20. Following the sale, the chief accounting officer now directly owns 43,949 shares of the company’s stock, valued at $6,930,757.30. The disclosure for this sale can be found here. 4.03% of the stock is owned by corporate insiders.

ALXN has been the topic of a number of recent analyst reports. Svb Leerink cut their price objective on shares of Alexion Pharmaceuticals from $163.00 to $159.00 and set an “outperform” rating on the stock in a report on Friday, October 30th. Piper Sandler lowered shares of Alexion Pharmaceuticals from an “overweight” rating to a “neutral” rating in a research note on Thursday, February 4th. Royal Bank of Canada upped their target price on shares of Alexion Pharmaceuticals from $139.00 to $175.00 and gave the company an “outperform” rating in a research note on Monday, December 14th. TheStreet upgraded shares of Alexion Pharmaceuticals from a “c” rating to a “b” rating in a research note on Thursday, October 29th. Finally, Sanford C. Bernstein started coverage on shares of Alexion Pharmaceuticals in a research note on Thursday, November 19th. They issued a “market perform” rating and a $148.00 target price on the stock. Eighteen investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $151.28.

Alexion Pharmaceuticals stock opened at $154.81 on Tuesday. The firm has a 50 day simple moving average of $156.61 and a 200-day simple moving average of $130.20. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.81 and a quick ratio of 3.26. The stock has a market capitalization of $34.03 billion, a PE ratio of 36.17, a price-to-earnings-growth ratio of 0.75 and a beta of 1.33. Alexion Pharmaceuticals, Inc. has a 12-month low of $72.67 and a 12-month high of $162.60.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Wednesday, February 3rd. The biopharmaceutical company reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.56 by $0.40. The business had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.51 billion. Alexion Pharmaceuticals had a net margin of 16.32% and a return on equity of 23.16%. The business’s revenue was up 15.0% on a year-over-year basis. During the same period last year, the firm posted $2.71 earnings per share. On average, analysts forecast that Alexion Pharmaceuticals, Inc. will post 11.14 earnings per share for the current fiscal year.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).

See Also: What is the CAC 40 Index?

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.